Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

Recent & Breaking News (TSX:ONC)

Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights

Accesswire November 12, 2019

Oncolytics Biotech(R) Announces Exercise of Warrants

Accesswire November 12, 2019

Oncolytics Biotech(R) Announces AWARE-1 Data Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

Accesswire November 8, 2019

Market Movers: Oncolytics Biotech, Xerox and Office Depot

Livemoney November 6, 2019

Oncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma

Accesswire November 6, 2019

Oncolytics Biotech(R) Provides Update on Partner Adlai Nortye's Clinical Progress

Accesswire October 31, 2019

Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer

Accesswire October 22, 2019

Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors

Accesswire October 17, 2019

Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors

Accesswire October 15, 2019

Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

Accesswire October 1, 2019

Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta

Accesswire September 30, 2019

Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference

Accesswire September 25, 2019

Oncolytics Biotech(R) Announces Upcoming Conference Participation

Accesswire September 23, 2019

Oncolytics Biotech(R) Receives Nasdaq Notification Letter

Accesswire September 20, 2019

Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference

Accesswire September 17, 2019

Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Accesswire September 5, 2019

Oncolytics Biotech(R) to Host Corporate Update Call to Discuss Recent Highlights and Expanded Catalysts and Milestones

Accesswire September 4, 2019

Oncolytics Biotech(R) Announces Closing of Its Public Offering of Common Shares and Warrants

Accesswire August 16, 2019

CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants

Accesswire August 14, 2019

Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants

Accesswire August 14, 2019